Amneal Reports Third Quarter 2026 Financial Results

Amneal posts strong revenue and EBITDA growth but reports a GAAP net loss on acquisition costs.

What the company is saying

Amneal Pharmaceuticals, Inc. emphasizes robust operational momentum, highlighting a 10% year-over-year increase in net revenue to $863 million for Q3 2026 and a 30% rise in adjusted EBITDA to $207 million. The company attributes segment growth to biosimilars, women’s health patches, and branded products such as CREXONT, BREKIYA autoinjector, and UNITHROID. Management, led by Co-Founders and Co-CEOs Chirag and Chintu Patel, frames the Kashiv acquisition as a catalyst for long-term biosimilars growth and signals confidence by raising 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS. The narrative is forward-leaning, stressing new launches and integration progress, while acknowledging that higher revenue and gross profit were offset by non-recurring acquisition and integration costs and a higher tax provision, resulting in a $22 million net loss. The company provides detailed guidance updates, explicitly quantifying new targets and discrete items excluded from cash flow projections. The tone is optimistic, with repeated references to accelerating performance and a robust growth outlook.

What the data suggests

The disclosed figures show Amneal’s Q3 2026 net revenue at $863 million, up from $785 million a year earlier, with Affordable Medicines and Specialty segments growing 19% and 20% respectively, while AvKARE declined 17% due to a prior-year one-off. Adjusted EBITDA rose 30% to $207 million, and adjusted diluted EPS jumped 53% to $0.26. Despite these operational gains, the company swung to a $22 million GAAP net loss from a $2 million profit, driven by $40 million in Kashiv acquisition and integration costs, $36 million in opioid settlement costs, and a higher tax provision. Diluted loss per share was $(0.06), compared to $0.01 earnings per share last year. Full-year 2026 guidance was raised: net revenue to $3.15–$3.25 billion, adjusted EBITDA to $800–$815 million, and adjusted diluted EPS to $1.04–$1.08. Operating cash flow guidance was revised to $325–$375 million, with capital expenditures expected at ~$150 million. The company’s results are supported by detailed GAAP and non-GAAP disclosures, but the absence of GAAP profitability and reliance on adjusted metrics highlight the impact of non-recurring costs.

Analysis

The announcement presents a positive tone, highlighting double-digit revenue growth, strong adjusted EBITDA, and a significant increase in adjusted EPS. These realised results are supported by disclosed GAAP and non-GAAP figures. However, the company also reports a net loss attributable to non-recurring acquisition and integration costs, and higher tax provision, which offsets the operational gains. The guidance increases for full-year 2026 revenue, EBITDA, and EPS are forward-looking and based on management's expectations, not yet realised. Capital expenditures of ~$150 million and discrete costs related to opioid settlements and acquisitions are substantial, with benefits from these outlays not immediately realised but expected within the next 6-14 months (near-term). The narrative is somewhat inflated by confident language about growth outlook and strategy, but the majority of claims are grounded in actual quarterly performance. The absence of a GAAP profit and the reliance on adjusted metrics cap the true signal at weak_positive.

Risk flags

• ●The company reported a $22 million GAAP net loss for Q3 2026 despite strong revenue and adjusted EBITDA growth, due to non-recurring acquisition, integration, and settlement costs. This raises concerns about the sustainability of profitability if such costs persist or recur.
• ●Adjusted metrics are emphasized over GAAP results, with adjusted EBITDA and EPS showing strong growth while GAAP net income remains negative. Investors must be cautious about the quality of earnings and the degree to which one-time items are excluded from headline results.
• ●Integration of the Kashiv acquisition is ongoing, and while management reports progress, the realization of expected synergies and long-term growth in biosimilars is not yet proven. Execution risk remains if integration costs or operational disruptions are higher than forecast.
• ●Operating cash flow guidance was revised downward, partly reflecting higher working capital and inventory levels in growth areas. This suggests cash conversion may lag profit growth and could pressure liquidity if inventory turns do not improve.
• ●The company faces ongoing legal and regulatory risks, including opioid settlement costs ($36 million excluded from guidance), which may continue to impact cash flow and profitability. Further legal liabilities or regulatory changes could materially affect results.

Bottom line

Amneal’s Q3 2026 results show strong operational growth, with net revenue up 10% and adjusted EBITDA up 30%, but the company remains unprofitable on a GAAP basis due to substantial acquisition, integration, and settlement costs. Management’s confidence is reflected in higher full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, but the improvement is largely in adjusted metrics, not net income. The Kashiv integration and biosimilars expansion are key to future growth, but execution risks around integration and realization of projected benefits remain. Cash flow guidance was revised downward, highlighting working capital pressures and the impact of discrete legal costs. Investors should focus on whether Amneal can translate adjusted performance into sustained GAAP profitability and improved cash generation in coming quarters. The most important takeaway is that while operational momentum is real, the path to consistent, unadjusted profitability is not yet secured.

Announcement summary

(NASDAQ:AMRX) Amneal Pharmaceuticals, Inc. reported its results for the third quarter ended September 30, 2026. Net revenue for the third quarter of 2026 was $863 million, representing an increase of 10% compared to $785 million in the third quarter of 2025. Affordable Medicines net revenue increased 19%, driven by biosimilars, women’s health patches, and new launches. Specialty net revenue increased 20%, driven by key branded products including CREXONT®, BREKIYA® autoinjector, and UNITHROID®. AvKARE net revenue decreased 17%, attributed to a non-recurring cardiovascular product launch in the prior year. Net loss attributable to Amneal Pharmaceuticals, Inc. was $22 million in the third quarter of 2026, compared to net income of $2 million in the third quarter of 2025, as higher revenue and gross profit were more than offset by non-recurring acquisition and integration costs, and higher tax provision. Adjusted EBITDA for the third quarter of 2026 was $207 million, an increase of 30% compared to the third quarter of 2025, reflecting higher revenue, higher gross profit, and lower operating expenses. Diluted loss per share in the third quarter of 2026 was $(0.06), compared to diluted income per share of $0.01 for the third quarter of 2025, due to the aforementioned factors and higher share count as a result of the Kashiv acquisition. Adjusted diluted earnings per share in the third quarter of 2026 was $0.26, an increase of 53% compared to $0.17 for the third quarter of 2025. Amneal increased its 2026 full year guidance for net revenue to a range of $3.15 billion to $3.25 billion, up from prior guidance of $3.10 billion to $3.20 billion. Adjusted EBITDA guidance was raised to $800 million to $815 million, from $750 million to $780 million previously. Adjusted diluted EPS guidance was increased to $1.04 to $1.08, from $0.96 to $1.06. Operating cash flow guidance was updated to $325 million to $375 million, from $350 million to $400 million previously. Operating cash flow excluding discrete items is now guided to $350 million to $400 million, from $375 million to $425 million previously. Capital expenditures for 2026 are expected to be approximately $150 million. Discrete items excluded from operating cash flow include opioid settlement costs of approximately $36 million and Kashiv acquisition and integration costs of approximately $40 million. The company’s 2026 estimates are based on management’s current expectations, including prescription trends, pricing levels, timing of future product launches, costs and benefits of restructuring activities, and long-term strategy. Amneal’s financial statements are prepared in accordance with GAAP. The company cannot provide a reconciliation between non-GAAP projections and the most directly comparable GAAP measures without unreasonable efforts due to the unpredictability of certain significant items. Amneal will host a conference call and live webcast at 8:30 am Eastern Time on November 3, 2026, to discuss its results.

Disagree with this article?